Skip to main content

Carina Biotech

October 18, 2023
Franciscan B
Gene/Cell Therapy
Company Description: Carina Biotech is a private Australian immunotherapy company established to research and develop chimeric antigen receptor T cell (CAR-T) therapies to treat solid cancers. CAR-T therapy is a revolutionary new treatment option that uses a patient’s immune system to fight their cancer. Carina has a pipeline of novel CAR-T programs for the treatment of a range of solid cancers, with the lead program targeting LGR5, a cancer stem cell marker in Phase 1 for the treatment of metastatic colon cancer. The company has also developed a proprietary multi-functional chemokine receptor platform to enable CAR-T cell arming, homing and access to tumors and an efficient CAR-T cell manufacturing platform to increase efficacy through serial cancer cell killing and persistence within tumors.
Deborah Rathjen, CEO - Carina Biotech


South Australia




CEO/Top Company Official


Lead Product in Development

LGR5 CAR T cell therapy CNA3103 for treatment of advanced colorectal, gastric, and ovarian cancers, and neuroblastoma. About CNA3103 Carina’s proprietary CNA3103 CAR-T cell targets LGR5, a cancer stem cell marker that is highly expressed on advanced colorectal cancer and some other cancers. In colorectal cancer patients, LGR5 expression has been correlated with poor prognosis. Cancer stem cells are a small sub-population of cells within a tumour with the ability to self-renew, differentiate into the many cell types of a tumour, initiate new tumours, and resist chemotherapy and radiotherapy (leading to relapses). By targeting cancer stem cells, it is hoped that this therapy will reduce the tumour’s ability to generate new cancer cells, resulting in durable tumour suppression and preventing the relapses that are very common in patients with colorectal cancer. Carina’s pre-clinical studies of CNA3103 have shown promising results with complete tumour regression and no tumour recurrence following a single administration. CNA3103 has also demonstrated enhanced tumour access and prolonged survival enabling rejection of new tumours.

Development Phase of Primary Product

Phase I

Number Of Unlicensed Products